[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Kawamori
Ryuzo
R
Kadowaki
Takashi
T
Ishida
Hitoshi
H
D000284:Administration, Oral; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003510:Cyclohexanes; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000145:classification / Q000494:pharmacology*; D007211:Indoles; D007294:Inositol / Q000031:analogs & derivatives*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D054833:Isoindoles; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives; D012307:Risk Factors; D013268:Stimulation, Chemical; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones
D003510:Cyclohexanes; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007211:Indoles; D007328:Insulin; D054833:Isoindoles; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000077715:Nateglinide; D010649:Phenylalanine; D007294:Inositol; C089946:2,4-thiazolidinedione; C087255:mitiglinide; C102817:voglibose